Advertisement
Screener

Oruka Therapeutics, Inc. (ORKA) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Oruka Therapeutics, Inc. Financing Cash Flow

Oruka Therapeutics, Inc. (ORKA) reported Financing Cash Flow of $703.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-10

  • Oruka Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $663.04M.
  • Oruka Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $40.60M.
  • Oruka Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $298.00K.
  • Oruka Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $169.91M.
  • Oruka Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $170.31M.
  • Oruka Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $0.00.
  • Oruka Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
  • Oruka Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2021 was $23.09M, a 52.34% decline from fiscal 2020.
Period endNet Cash Provided by (Used in) Financing Activities 2 monthNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 5 monthNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 8 monthNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 11 monthNet Cash Provided by (Used in) Financing Activities 12 monthNet Cash Provided by (Used in) Financing Activities 114 monthNet Cash Provided by (Used in) Financing Activities 117 monthNet Cash Provided by (Used in) Financing Activities 120 monthNet Cash Provided by (Used in) Financing Activities 123 monthNet Cash Provided by (Used in) Financing Activities 126 monthNet Cash Provided by (Used in) Financing Activities 129 monthNet Cash Provided by (Used in) Financing Activities 132 monthNet Cash Provided by (Used in) Financing Activities 135 monthNet Cash Provided by (Used in) Financing Activities 138 monthNet Cash Provided by (Used in) Financing Activities 141 monthNet Cash Provided by (Used in) Financing Activities 144 month
2026-06-30$663.04M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
$703.64M
10-Q · filed 2026-08-10
$703.94M
derived: sum of 3 quarters · filed 2026-08-10
$873.85M
derived: sum of 4 quarters · filed 2026-08-10
2026-03-31$40.60M
10-Q · filed 2026-05-13
$40.90M
derived: sum of 2 quarters · filed 2026-05-13
$210.81M
derived: sum of 3 quarters · filed 2026-05-13
2025-12-31$298.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$170.21M
derived: sum of 2 quarters · filed 2026-03-12
$170.31M
10-K · filed 2026-03-12
2025-09-30$169.91M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$170.02M
10-Q · filed 2025-11-12
2025-06-30$109.00K
10-Q · filed 2026-08-10
2024-12-31$449.54M
10-K · filed 2026-03-12
2024-09-30$450.06M
10-Q · filed 2025-11-12
2024-06-30$14.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01
$26.32M
10-Q · filed 2025-08-11
$14.00K
10-Q · filed 2024-08-01
2024-03-31$27.91M
10-Q · filed 2025-05-14
$0.00
10-Q · filed 2024-04-25
2023-12-31$0.00
10-K · filed 2024-02-01
2023-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01
$0.00
10-Q · filed 2024-08-01
2023-03-31$0.00
10-Q · filed 2024-04-25
2022-12-31$0.00
10-K · filed 2024-02-01
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24
$0.00
derived: sum of 2 quarters · filed 2023-02-24
$0.00
derived: sum of 3 quarters · filed 2023-02-24
$23.09M
10-K · filed 2023-02-24
2021-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28
$0.00
derived: sum of 2 quarters · filed 2022-10-28
$23.09M
10-Q · filed 2022-10-28
$24.08M
derived: sum of 4 quarters · filed 2022-10-28
2021-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02
$23.09M
10-Q · filed 2022-08-02
$24.08M
derived: sum of 3 quarters · filed 2022-08-02
$66.13M
derived: sum of 4 quarters · filed 2022-08-02
2021-03-31$23.09M
10-Q · filed 2022-05-02
$24.08M
derived: sum of 2 quarters · filed 2022-05-02
$66.13M
derived: sum of 3 quarters · filed 2022-05-02
2020-12-31$984.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14
$43.04M
derived: sum of 2 quarters · filed 2022-03-14
$48.45M
10-K · filed 2022-03-14
2020-09-30$42.06M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02
$47.47M
10-Q · filed 2021-11-02
2020-06-30$5.41M
10-Q · filed 2021-08-04
2019-12-31-$122.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18
$446.00K
derived: sum of 2 quarters · filed 2021-03-18
$3.60M
derived: sum of 3 quarters · filed 2021-03-18
$6.56M
10-K · filed 2021-03-18
2019-09-30$568.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02
$3.72M
derived: sum of 2 quarters · filed 2020-11-02
$6.68M
10-Q · filed 2020-11-02
$6.58M
derived: sum of 4 quarters · filed 2020-11-02
2019-06-30$3.15M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05
$6.11M
10-Q · filed 2020-08-05
$6.01M
derived: sum of 3 quarters · filed 2020-08-05
$6.01M
derived: sum of 4 quarters · filed 2020-08-05
2019-03-31$2.96M
10-Q · filed 2020-05-06
$2.86M
derived: sum of 2 quarters · filed 2020-05-06
$2.86M
derived: sum of 3 quarters · filed 2020-05-06
$2.65M
derived: sum of 4 quarters · filed 2020-05-06
2018-12-31-$105.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-18
-$105.00K
derived: sum of 2 quarters · filed 2020-02-18
-$312.00K
derived: sum of 3 quarters · filed 2020-02-18
$3.10M
10-K · filed 2020-02-18
2018-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06
-$207.00K
derived: sum of 2 quarters · filed 2019-11-06
$3.21M
10-Q · filed 2019-11-06
$3.22M
derived: sum of 4 quarters · filed 2019-11-06
2018-06-30-$207.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01
$3.21M
10-Q · filed 2019-08-01
$3.22M
derived: sum of 3 quarters · filed 2019-08-01
$7.16M
derived: sum of 4 quarters · filed 2019-08-01
2018-03-31$3.42M
10-Q · filed 2019-05-08
$3.42M
derived: sum of 2 quarters · filed 2019-05-08
$7.37M
derived: sum of 3 quarters · filed 2019-05-08
2017-12-31$7.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27
$3.95M
derived: sum of 2 quarters · filed 2019-02-27
$5.85M
10-K · filed 2019-02-27
2017-09-30$3.95M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14
$5.84M
10-Q · filed 2018-11-14
2017-06-30$1.89M
10-Q · filed 2018-08-09
2013-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-20
-$55.00K
derived: sum of 2 quarters · filed 2014-03-20
$17.77M
derived: sum of 3 quarters · filed 2014-03-20
$19.16M
10-K · filed 2014-03-20
$74.44M
10-K · filed 2014-03-20
2013-09-30-$55.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13
$17.77M
derived: sum of 2 quarters · filed 2013-11-13
$19.16M
10-Q · filed 2013-11-13
$19.66M
derived: sum of 4 quarters · filed 2014-03-20
$74.44M
10-Q · filed 2013-11-13
2013-06-30$17.82M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-13
$19.21M
10-Q · filed 2013-08-13
$19.72M
derived: sum of 3 quarters · filed 2014-03-20
$20.39M
derived: sum of 4 quarters · filed 2014-03-20
$74.50M
10-Q · filed 2013-08-13
2013-03-31$1.39M
10-Q · filed 2013-05-13
$1.90M
derived: sum of 2 quarters · filed 2014-03-20
$2.57M
derived: sum of 3 quarters · filed 2014-03-20
$2.50M
derived: sum of 4 quarters · filed 2014-03-20
$56.68M
10-Q · filed 2013-05-13
2012-12-31$508.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-20
$1.18M
derived: sum of 2 quarters · filed 2014-03-20
$1.11M
derived: sum of 3 quarters · filed 2014-03-20
$1.05M
10-K · filed 2014-03-20
$55.29M
10-K · filed 2013-03-21
2012-09-30$674.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13
$607.00K
derived: sum of 2 quarters · filed 2013-11-13
$547.00K
10-Q · filed 2013-11-13
$1.97M
derived: sum of 4 quarters · filed 2013-11-13
$54.78M
10-Q · filed 2012-11-13
2012-06-30-$67.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-13
-$127.00K
10-Q · filed 2013-08-13
$1.30M
derived: sum of 3 quarters · filed 2013-08-13
$1.26M
derived: sum of 4 quarters · filed 2013-08-13
$54.10M
10-Q · filed 2012-08-13
2012-03-31-$60.00K
10-Q · filed 2013-05-13
$1.37M
derived: sum of 2 quarters · filed 2013-05-13
$1.33M
derived: sum of 3 quarters · filed 2013-05-13
$54.17M
10-Q · filed 2012-05-14
2011-12-31$1.43M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-21
$1.39M
derived: sum of 2 quarters · filed 2013-03-21
$3.87M
10-K · filed 2013-03-21
$54.23M
10-K · filed 2012-03-27
2011-09-30-$40.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-13
$2.44M
10-Q · filed 2012-11-13
$52.81M
10-Q · filed 2011-11-14
2011-06-30$2.48M
10-Q · filed 2012-08-13
$52.85M
10-Q · filed 2011-08-15
2010-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-27
$1.00K
derived: sum of 2 quarters · filed 2012-03-27
$7.32M
10-K · filed 2012-03-27
2010-09-30$1.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14
$7.32M
10-Q · filed 2011-11-14
2010-06-30$7.32M
10-Q · filed 2011-08-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07
Dianthus Therapeutics, Inc. /DE/ (DNTH)United States$5.082B-27.79
Erasca, Inc. (ERAS)United States$5.073B-19.96
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
Liquidia Corp (LQDA)United States$6.347B51.23
Veradermics, Inc (MANE)United States$4.839B